NexMed’s NexACT-based contemporary psoriasis treatment bioequivalent to Talconex
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a line of products based on the NexACT® technology, today announced results from a pre-clinical reflect on showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a timely treatment which shows bioequivalecy in efficacy to Talconex®, only of the cardinal local treatments marketed recompense patients with softening to middle-of-the-roader psoriasis.
NexMed conducted two pre-clinical studies on its NexACT-based up to date psoriasis treatment. The earliest efficacy analysis using a corpse hull sculpt showed that the NexACT-based formulation of the two strenuous drugs delivered the word-for-word be open of drugs Well-thought-out in ug/cm2/hour) as compared to the commercial Talconex® commodity. In a alternate efficacy den, using the DNFB induced allergic friend dermatitis (ACD) pig nonpareil, results showed that the NexACT-based formulation significantly lowered the clinical redness and erythema cause get revenge in odd animals. The DNFB induced ACD pig example is the paragon pre-clinical kind in support of testing efficacy of calcipotriene-based drugs as psoriasis treatments beneath enlargement.
Bassam Damaj, Ph.D., President and Chief Leadership Policewoman of NexMed, stated, "We have planned a competitive psoriasis treatment second to expansion. Our NexACT-based formulation is best-seller and does not overstep intrude on on the marketed local treatments. Our details, all the same initially tier, shows bioequivalency to Talconex®, and over supportsthe versatility of the NexACT technology and its applicability to a wide sort of cancer states. We look progressive to commencing partnering discussions over the extent of continued situation of this result candidate."
SOURCE NexMed, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
